ELSEVIER

European Journal of Pharmacology 428 (2001) 389–390

ejp

www.elsevier.com/locate/ejphar

Corrigendum to "Neuropharmacological profiles of a novel atypical antipsychotic, NRA0562, in rats" [Eur. J. Pharmacol. 423 (2001) 27–33]☆

Naoya Kawashima*, Takeo Funakoshi, Tomohiro Omura, Shigeyuki Chaki, Kazuya Kameo, Shigeru Okuyama

CNS Diseases Research, Medicinal Pharmacology Laboratory, Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama 330-8530, Japan

The authors regret that in the above-mentioned article errors were made.

The following points need to be considered: Figs. 3 and 4 should change place with each other. Fig. 3 should show recording data of electrophysiology and Fig. 4 should show graphs. The legends are correct. The correct figures plus legends are given on the following page.

☆ PII of original article S0014-2999(01)01085-8

* Corresponding author.

E-mail address: n.kawashima@po.rd.taisho.co.jp (N. Kawashima).

PII: S0014-2999(01)01292-4



Fig. 3. Reversal by NRA0562 of the inhibitory effects of methamphetamine (1 mg/kg, i.v.) on A10 (A) and A9 (B) dopamine neurons.



Fig. 4. Comparison of the potential of NRA0562 (A) and risperidone (B) to reverse the inhibitory effects of methamphetamine (1 mg/kg, i.v.) on A10 () and A9 () dopamine neurons. The results are presented as means with vertical lines showing S.E. ($n = 6$). Starting doses of NRA0562 and risperidone were 0.1 and 0.01 mg/kg, i.v., respectively. $^{**}P < 0.01$ vs. pre-drug value (Dunnett's test). $^{\#\#}P < 0.01$ vs. methamphetamine + vehicle-treated group (Dunnett's test).